Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Pleural Epithelioid Mesothelioma

Tundra lists 2 Pleural Epithelioid Mesothelioma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07121374

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

The goal of this clinical trial is to evaluate whether a combination of chemotherapy and immunotherapy can make surgery possible in adults with inoperable pleural mesothelioma (a type of cancer affecting the lung lining). The main questions it aims to answer are: Can two cycles of neoadjuvant chemotherapy and dual immunotherapy, followed by surgery, be completed safely and effectively? Does this treatment allow previously inoperable patients to become eligible for surgery and improve survival outcomes? Participants will: Receive two cycles of chemotherapy (cisplatin or carboplatin and pemetrexed) Receive dual immunotherapy (nivolumab and ipilimumab) Undergo evaluation by a multidisciplinary team to determine if surgery is possible If operable, undergo extended pleurectomy/decortication surgery Be followed for one year to assess side effects, quality of life, and survival

Gender: All

Ages: 18 Years - Any

Updated: 2025-08-13

1 state

Pleural Epithelioid Mesothelioma
Mesothelioma; Pleura
Neoadjuvant Chemoimmunotherapy
ACTIVE NOT RECRUITING

NCT02399371

Pembrolizumab in Treating Patients With Malignant Mesothelioma

This phase II trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death 1 (PD-1) which may stimulate an immune response and kill tumor cells.

Gender: All

Ages: 18 Years - Any

Updated: 2025-06-11

1 state

Biphasic Mesothelioma
Epithelioid Mesothelioma
Peritoneal Malignant Mesothelioma
+7